Visual Function and Freedom from Disease Activity in a Phase 3 Trial for Relapsing Multiple Sclerosis

Update item information
Identifier 20130212_nanos_posters_005
Title Visual Function and Freedom from Disease Activity in a Phase 3 Trial for Relapsing Multiple Sclerosis
Creator Balcer, Laura J; Galetta, Steven L; Zhang, Annie; Arnold, Ryan
Subject Visual Function; Multiple Sclerosis; Low-Contrast Letter Acuity; Natalizumab
Description In the phase 3 trial of natalizumab for relapsing MS (AFFIRM), low-contrast letter acuity (LCA) showed decreased probability of sustained visual loss in patients receiving active treatment. Freedom from clinical and radiological disease activity was also seen in 37% of treated patients over 2 years in AFFIRM. Given the importance of vision to overall functioning and quality of life in MS, we determined how freedom from disease activity might be associated with visual loss.
Relation is Part of NANOS 2013: Poster Presentations
Publisher Spencer S. Eccles Health Sciences Library, University of Utah
Date 2013-02-12
Type Text
Format application/pdf
Format Creation application/pdf
Source 2013 North American Neuro-Ophthalmology Society Annual Meeting
Rights Management Copyright 2013. For further information regarding the rights to this collection, please visit: https://NOVEL.utah.edu/about/copyright
Holding Institution North American Neuro-Ophthalmology Association. NANOS Executive Office 5841 Cedar Lake Road, Suite 204, Minneapolis, MN 55416
Collection Neuro-ophthalmology Virtual Education Library: NOVEL http://NOVEL.utah.edu
Language eng
ARK ark:/87278/s6dn7brf
Setname ehsl_novel_nam
Date Created 2014-01-08
Date Modified 2014-01-08
ID 183354
Reference URL https://collections.lib.utah.edu/ark:/87278/s6dn7brf
Back to Search Results